Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML

Arsenic on the Fingers Arsenic, an ancient drug used in traditional Chinese medicine, has attracted wide interest because it has therapeutic activity in patients with acute promyelocytic leukemia (APL). The drug acts by promoting degradation of an oncogenic protein, PML-RARα, a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor α, which is found specifically in APL cells and helps drive their growth. Zhang et al. (p. 240; see the Perspective by Kogan) now explain how arsenic initiates the molecular events leading to PML-RARα degradation. Arsenic was found to bind directly to cysteine residues within zinc finger domains of PML. Arsenic binding then induced oligomerization of PML, which in turn enhanced its association with an enzyme that helps catalyze SUMOylation, a posttranslational modification that can target proteins for degradation. Arsenic, a drug used clinically for leukemia, binds directly to an oncogenic protein, thereby promoting its degradation. Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARα (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RARα degradation is triggered by their SUMOylation, but the mechanism by which As2O3 induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RARα and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)–conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As2O3 provides new insights into the drug’s mechanism of action and its specificity for APL.

[1]  A. Holmgren,et al.  Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide , 2007, Proceedings of the National Academy of Sciences.

[2]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[3]  V. Lallemand-Breitenbach,et al.  How acute promyelocytic leukaemia revived arsenic , 2002, Nature Reviews Cancer.

[4]  Paul Freemont,et al.  Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation , 2001, The Journal of experimental medicine.

[5]  P. Freemont,et al.  In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Pandolfi,et al.  Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation , 2008, Nature Medicine.

[7]  Brent R. Martin,et al.  Mammalian cell–based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity , 2005, Nature Biotechnology.

[8]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[9]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[10]  E. Estey,et al.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.

[11]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[12]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[13]  P. Freemont,et al.  PML protein isoforms and the RBCC/TRIM motif , 2001, Oncogene.

[14]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[15]  D. E. Anderson,et al.  Identification of arsenic-binding proteins in human breast cancer cells. , 2007, Cancer letters.

[16]  Guang-Biao Zhou,et al.  Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.

[17]  C. Natoli,et al.  The MXAN procedure: a new method for analysing the XANES spectra of metalloproteins to obtain structural quantitative information. , 2003, Journal of synchrotron radiation.

[18]  P. Freemont,et al.  SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. , 1999, Journal of cell science.

[19]  P. Freemont,et al.  The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto‐oncoprotein PML. , 1995, The EMBO journal.

[20]  H. de Thé,et al.  Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[22]  Yasuo Ikeda,et al.  PML targeting eradicates quiescent leukaemia-initiating cells , 2008, Nature.

[23]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[24]  M. Lei,et al.  Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway , 2008, Nature Cell Biology.

[25]  X. Le,et al.  Interaction of trivalent arsenicals with metallothionein. , 2003, Chemical research in toxicology.

[26]  M. Tatham,et al.  RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation , 2008, Nature Cell Biology.

[27]  B. Rosen,et al.  Spatial Proximity of Cys113, Cys172, and Cys422 in the Metalloactivation Domain of the ArsA ATPase* , 1996, The Journal of Biological Chemistry.

[28]  A. Spuches,et al.  Thermodynamics of the As(III)-thiol interaction: arsenite and monomethylarsenite complexes with glutathione, dihydrolipoic acid, and other thiol ligands. , 2005, Inorganic chemistry.